|
Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
Medical Xpress “The combination of the established antibody drug rituximab with the experimental drug pidilizumab so far also has a remarkably mild side effect profile,” Neelapu said. Of 29 study participants at a median follow-up of 15.4 months, 19 (66 percent) had … |
|
Idelalisib With Rituximab Boosts Survival in Relapsed CLL
Medscape In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. “Idelalisib is a targeted, highly selective, orally … Idelalisib plus rituximab extended survival in previously treated CLLHealio Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gilead’s Pipeline EncouragesYahoo News |
|
Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies …
Benzinga Roche (OTC: RHHBY) and Prothena Corporation plc (Nasdaq: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal … Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co …MarketWatch Roche, Prothena ink potential $600 million deal for Parkinson’s diseaseSan Francisco Business Times (blog) RTT News –Seeking Alpha all 10 news articles » |
|
Dr. Reddy’s Targets Roche’s Rituxan in Europe: Corporate India
Businessweek Making a version of rituximab, the ingredient in cancer-treatment Rituxan, is where “the big opportunity is in the developed markets, clearly; that’s where the big sales are,” he said. Dr. Reddy’s joins larger rivals including Novartis AG and Pfizer … |
|
New CLL Therapy Beats Standard Protocol
MedPage Today The findings suggest that the new drug is “equally safe yet more powerful” than rituximab, commented Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute in Boston, who was not involved in the study but who moderated a press conference at which … |
|
Data on Monoclonal Antibodies Detailed by Researchers at University Health …
HispanicBusiness.com By a News Reporter-Staff News Editor at Women’s Health Weekly — Fresh data on Drugs and Therapies are presented in a new report. According to news reporting from Toronto, Canada , by NewsRx journalists, research stated, “Block copolymer micelles … |
|
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL
Cancer Network The progression-free survival (PFS) rate at 24 weeks was 93% for patients treated with idelalisib plus rituximab compared with 46% for patients treated with rituximab alone. The median PFS of the combination arm has not yet been reached. The median PFS … Idelalisib plus rituximab extended survival in previously treated CLLHealio Gilead’s Pipeline EncouragesYahoo News |
|
Idelalisib plus rituximab extended survival in previously treated CLL
Healio NEW ORLEANS — The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results presented at the ASH Annual Meeting and Exposition. Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gileads Pipeline EncouragesZacks.com |
OncLive |
Latest Data Further Support Ibrutinib’s Efficacy in CLL
OncLive Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30 … Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell MalignanciesMarketWatch |
|
Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in …
4-traders (press release) In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an … |